Current status of cardiac transplantation and mechanical circulatory support
- First Online:
Cardiac transplantation and mechanical circulatory support are possible options for improving survival and quality of life in patients with isolated cardiac disease and end-stage heart failure. Transplantation is limited by donor availability but has a median survival of 10 years. Post-transplant immunosuppression is often transplant center dependent, but a tacrolimus and mycophenolate mofetil-based regimen may be preferred. Sirolimus may reduce the progression rate of transplant vasculopathy. There has been a trend toward continuous-flow left ventricular assist devices because of their increased durability and reduced size. A variety of surgical and percutaneous ventricular assist devices may be used as a bridge to decision on a patient’s candidacy for transplantation. Mechanical circulatory support as destination therapy has not been widely implemented because of poor device durability, but this is expected to change with newer devices. Mechanical circulatory support as a bridge to myocardial recovery has been successful only in a few patients.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 19.Russell SD, Dyke DB, Aranda JM, et al.: Renal and hepatic function improve in advanced heart failure patients during continuous flow support with the HeartMate II LVAD [abstract 144]. Presented at the 11th Annual Scientific Meeting of the Heart Failure Society of America. Washington DC; September 16–19, 2007.Google Scholar
- 20.Boyle AJ, Griffith B, Ascheim D, et al.: The VentrAssist LVAD as a bridge to cardiac transplantation: results on the US feasibility trial [abstract 518]. Presented at the International Society of Heart and Lung Transplantation 28th Annual Meeting and Scientific Sessions. Boston, MA; April 9–12, 2008.Google Scholar
- 23.Boyle AJ, Teuteberg JJ, Ascheim D, et al.: LVADs for less acutely ill patients: do current data justify the strategy? Presented at the 54th American Society of Artificial Internal Organs Annual Conference. San Francisco, CA; June 19–21, 2008.Google Scholar
- 25.Burkhoff D, Cohen H, Brunckhorst C, et al.: A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 2006, 152:469.e1–469.e8.CrossRefGoogle Scholar
- 27.Greenberg B, Czerska B, Delgado RM, et al.: Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). Circulation 2008, 118:1241–1249.PubMedCrossRefGoogle Scholar